IRVINE, Calif. & KIEL, Germany & CAIRO, Egypt--(BUSINESS WIRE)--Proteo, Inc. (OTCBB: PTEO; Frankfurt Freiverkehr: WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG together with Minapharm Pharmaceuticals SAE (Cairo and Alexandria Stock Exchange: MIPH) and its subsidiary Rhein Minapharm Biogenetics SAE announced today that the responsible authority in Cairo has granted approval for a Phase II clinical trial to study the efficacy of Elafin on kidney transplant patients.
